Teva’s (TEVA) $125 Million BioXcel Bid Offers Upside, but FDA and Auction Risks Remain
Teva Pharmaceutical Industries Limited (NYSE:TEVA) has agreed to serve as the stalking-horse bidder for substantially all of BioXcel Therapeutics, Inc.
Bioxcel Therapeutics Inc. (BTAI)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Millennium Management Israel Englander | 2,114,710 | $2,981,741 | +10% | 0% |
| 2. | Oaktree Capital Management Howard Marks | 1,380,248 | $1,946,150 | +473% | 0.03% |
| 3. | Citadel Investment Group Ken Griffin | 149,220 | $210,400 | 0% | |
| 4. | Armistice Capital Steven Boyd | 0 | $0 | 0% | |
| 5. | GLG Partners Noam Gottesman | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.00 | 2,000 | $22,000.00 | 2,000 | 2018-03-12 | Filing | |
| $9.34 | 1,554 | $14,514.36 | 168,320 | 2019-08-23 | Filing | |
| $8.83 | 6,646 | $58,684.18 | 166,766 | 2019-08-22 | Filing | |
| $8.42 | 1,800 | $15,156.00 | 160,120 | 2019-08-21 | Filing | |
| $8.89 | 974 | $8,658.86 | 9,957 | 2019-08-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.09 | 6,845 | $7,426.83 | 26,175 | 2026-05-20 | Filing | |
| $1.08 | 6,560 | $7,111.04 | 26,803 | 2026-05-20 | Filing | |
| $1.09 | 6,845 | $7,426.83 | 26,300 | 2026-05-20 | Filing | |
| $1.09 | 19,419 | $21,108.45 | 69,598 | 2026-05-20 | Filing | |
| $0.35 | 165 | $58.13 | 19,957 | 2024-12-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 919,545 | $1,296,558 | 0% | |
| 2. | 245,585 | $346,274 | 0.6% | |
| 3. | 242,251 | $341,911 | 0% | |
| 4. | 179,433 | $253,001 | 0% | |
| 5. | 158,065 | $222,871 | 0% |
News See All
H.C. Wainwright Adjusts BioXcel Therapeutics, Inc. (BTAI) Outlook Following Capital Structure Concerns
We recently compiled a list of the 10 Best Beaten Down Stocks to Invest in According to Analysts. BioXcel Therapeutics, Inc. is one of the best 52-week low stocks. TheFly reported on April 2 that H.C.
10 Best Beaten Down Stocks to Invest in According to Analysts
In this article, we will be taking a look at the 10 Best Beaten Down Stocks to Invest in According to Analysts.
BioXcel Therapeutics, Inc. (BTAI) Retains Buy Rating on Positive Trial Progress
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is among the fundamentally strong penny stocks to invest in. H.C. Wainwright analysts have reiterated their Buy rating on BioXcel Therapeutics, Inc.
12 Best Fundamentally Strong Penny Stocks to Invest in
In this article, we will take a look at some of the fundamentally strong penny stocks to invest in.
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call Transcript November 14, 2024 Operator: Good morning, and welcome to the BioXcel Therapeutics Third Quarter 2024 Earnings Conference Call.
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call Transcript May 9, 2024 BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2023 Earnings Call Transcript March 12, 2024 BioXcel Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.76, expectations were $-0.98.
15 Hot Penny Stocks On the Move
In this article, we will take a detailed look at the 15 Hot Penny Stock On the Move. For a quick overview of such stocks, read our article 5 Hot Penny Stock On the Move.
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2023 Earnings Call Transcript November 14, 2023 BioXcel Therapeutics, Inc. misses on earnings expectations.
Hedge Fund Resource Center